Issue 10, 2017

Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer

Abstract

ALK-fusion proteins play a fundamental role in the development of about 5% of non-small cell lung cancers. Herein, we identified the compound 5067-0952 as a potent ALK inhibitor, which inhibited cell growth, induced apoptosis, and suppressed the phosphorylation of ALK, subsequently blocking its downstream signaling pathway.

Graphical abstract: Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer

Article information

Article type
Research Article
Submitted
21 Jun 2017
Accepted
24 Aug 2017
First published
25 Aug 2017

Med. Chem. Commun., 2017,8, 1914-1918

Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer

L. Luo, Y. Li, Y. Niu, Y. Wang, Q. Wang, X. Fan, J. Xu, L. Liu, E. L. Leung and X. Yao, Med. Chem. Commun., 2017, 8, 1914 DOI: 10.1039/C7MD00305F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements